[高胆固醇血症和实验室报告:意大利心脏病学会(SIC)和意大利临床生物化学和临床分子生物学-实验室医学学会(SIBioC)联合文件]。

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Stefania Paolillo, Maria Stella Graziani, Ciro Indolfi, Martina Zaninotto, Paolo Calabrò, Ferruccio Ceriotti, Francesco Barillà, Aldo Clerico, Marco Matteo Ciccone, Tommaso Trenti, Italo Porto, Marcello Ciaccio, Arturo Cesaro, Sara Fontanarosa, Mario Plebani, Pasquale Perrone Filardi
{"title":"[高胆固醇血症和实验室报告:意大利心脏病学会(SIC)和意大利临床生物化学和临床分子生物学-实验室医学学会(SIBioC)联合文件]。","authors":"Stefania Paolillo, Maria Stella Graziani, Ciro Indolfi, Martina Zaninotto, Paolo Calabrò, Ferruccio Ceriotti, Francesco Barillà, Aldo Clerico, Marco Matteo Ciccone, Tommaso Trenti, Italo Porto, Marcello Ciaccio, Arturo Cesaro, Sara Fontanarosa, Mario Plebani, Pasquale Perrone Filardi","doi":"10.1714/4336.43219","DOIUrl":null,"url":null,"abstract":"<p><p>Dyslipidemia is one of the most important risk factors for the development of atherosclerotic disease and its control, through well-proven therapies, allows an optimal risk management over time. LDL-cholesterol targets are well defined by international guidelines and based on individual cardiovascular risk. As guidelines evolve, also laboratory reports need to do the same, including lipid reference values by cardiovascular risk classes, to avoid misunderstandings and inappropriate lipid-lowering therapy withdrawal. The aim of the present joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC) is to analyze the importance of cardiovascular risk estimation, therapeutical targets, and crucial elements about dyslipidemia in laboratory tests, as well as to suggest a shared proposal for the report of lipid profile parameters to be applied to all clinical scenarios of our daily practice.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 10","pages":"756-762"},"PeriodicalIF":0.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Hypercholesterolemia and laboratory reports: joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC)].\",\"authors\":\"Stefania Paolillo, Maria Stella Graziani, Ciro Indolfi, Martina Zaninotto, Paolo Calabrò, Ferruccio Ceriotti, Francesco Barillà, Aldo Clerico, Marco Matteo Ciccone, Tommaso Trenti, Italo Porto, Marcello Ciaccio, Arturo Cesaro, Sara Fontanarosa, Mario Plebani, Pasquale Perrone Filardi\",\"doi\":\"10.1714/4336.43219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dyslipidemia is one of the most important risk factors for the development of atherosclerotic disease and its control, through well-proven therapies, allows an optimal risk management over time. LDL-cholesterol targets are well defined by international guidelines and based on individual cardiovascular risk. As guidelines evolve, also laboratory reports need to do the same, including lipid reference values by cardiovascular risk classes, to avoid misunderstandings and inappropriate lipid-lowering therapy withdrawal. The aim of the present joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC) is to analyze the importance of cardiovascular risk estimation, therapeutical targets, and crucial elements about dyslipidemia in laboratory tests, as well as to suggest a shared proposal for the report of lipid profile parameters to be applied to all clinical scenarios of our daily practice.</p>\",\"PeriodicalId\":12510,\"journal\":{\"name\":\"Giornale italiano di cardiologia\",\"volume\":\"25 10\",\"pages\":\"756-762\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale italiano di cardiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1714/4336.43219\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4336.43219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

血脂异常是动脉粥样硬化性疾病发生的最重要风险因素之一,通过行之有效的疗法对其进行控制,可以实现长期的最佳风险管理。低密度脂蛋白胆固醇的目标已由国际指南明确定义,并以个人心血管风险为基础。随着指南的不断发展,实验室报告也需要与时俱进,包括按心血管风险等级划分的血脂参考值,以避免误解和不适当的降脂治疗停药。本文件由意大利心脏病学会(SIC)和意大利临床生物化学和临床分子生物学-实验室医学学会(SIBioC)联合撰写,旨在分析心血管风险评估的重要性、治疗目标以及实验室检测中有关血脂异常的关键因素,并就血脂谱参数报告提出共同建议,以适用于我们日常实践中的所有临床情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Hypercholesterolemia and laboratory reports: joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC)].

Dyslipidemia is one of the most important risk factors for the development of atherosclerotic disease and its control, through well-proven therapies, allows an optimal risk management over time. LDL-cholesterol targets are well defined by international guidelines and based on individual cardiovascular risk. As guidelines evolve, also laboratory reports need to do the same, including lipid reference values by cardiovascular risk classes, to avoid misunderstandings and inappropriate lipid-lowering therapy withdrawal. The aim of the present joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC) is to analyze the importance of cardiovascular risk estimation, therapeutical targets, and crucial elements about dyslipidemia in laboratory tests, as well as to suggest a shared proposal for the report of lipid profile parameters to be applied to all clinical scenarios of our daily practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信